CLINICAL DEVELOPMENT & PHARMACOLOGY
Clinical Development & Pharmacology
Designing Smarter Trials. Improving Clinical Success.
Clinical development is the most resource-intensive and high-risk phase of drug development.
Poor trial design, suboptimal dosing strategies, or weak pharmacology insights can lead to
failed studies, delays, or regulatory setbacks.
Our advisory platform provides integrated clinical development and pharmacology expertise to ensure
that programs are scientifically robust, operationally efficient, and aligned with regulatory and commercial objectives.
Our Approach
Data-Driven, Model-Informed Development
We combine clinical strategy, pharmacology, and quantitative modeling to design programs that:
- Maximize probability of technical and regulatory success
- Optimize dose, schedule, and patient selection
- Reduce development timelines and costs
- Generate high-quality, decision-enabling data
Our approach emphasizes Model-Informed Drug Development (MIDD) to translate data into actionable decisions
throughout the clinical lifecycle.
Core Capabilities
1. Clinical Development Strategy
What We Do
- Design integrated clinical development plans (Phase I–III)
- Define target product profile (TPP) and clinical endpoints
- Develop indication and patient population strategy
- Align clinical strategy with regulatory and commercial objectives
Value
- Creates a clear roadmap to approval
- Reduces risk of misaligned or underpowered studies
- Improves overall program efficiency
2. First-in-Human (FIH) & Early Clinical Design
What We Do
- Design Phase I studies (SAD/MAD, food effect, DDI)
- Determine safe starting dose (NOAEL, MABEL approaches)
- Develop dose escalation strategies
- Assess safety monitoring frameworks
Value
- Enables safe and efficient entry into human trials
- Minimizes early clinical risk
- Establishes strong foundation for downstream development
3. Clinical Pharmacology & PK/PD
What We Do
- Characterize pharmacokinetics (ADME)
- Develop PK/PD and exposure-response models
- Support dose selection and optimization
- Evaluate variability across populations
Value
- Enables rational dosing decisions
- Improves efficacy and safety outcomes
- Supports regulatory acceptance of dosing strategy
4. Model-Informed Drug Development (MIDD)
What We Do
- Population PK/PD modeling
- Physiologically based pharmacokinetic (PBPK) modeling
- Simulation of clinical trial scenarios
- Exposure-response analysis
Value
- Reduces uncertainty in clinical decision-making
- Optimizes trial design and sample size
- Supports regulatory interactions and submissions
5. Late-Stage Clinical Strategy (Phase II/III)
What We Do
- Design pivotal trials (Phase II/III)
- Endpoint selection and statistical strategy
- Comparator and control arm design
- Risk-based study optimization
Value
- Increases probability of clinical success
- Reduces likelihood of costly trial failure
- Aligns studies with regulatory expectations
6. Special Populations & Clinical Pharmacology Studies
- Drug-drug interaction (DDI) studies
- Food effect studies
- Renal and hepatic impairment studies
- Pediatric and geriatric strategy
7. Biomarkers & Translational Integration
- Identify and validate clinical biomarkers
- Link preclinical and clinical endpoints
- Enable patient stratification
- Support proof-of-concept decisions
8. Regulatory Strategy for Clinical Development
- Prepare for FDA and global regulatory interactions
- Align programs with IND, NDA, and BLA expectations
- Support regulatory meetings
- Address regulatory questions and deficiencies
9. Clinical Operations & Execution Alignment
- Align clinical strategy with operational feasibility
- Support site selection and recruitment strategy
- Integrate clinical supply and manufacturing
- Optimize timelines and milestones
Integrated Expertise Across Modalities
- Small molecules
- Biologics and monoclonal antibodies
- Cell and gene therapies
- Vaccines
- Diagnostics and companion diagnostics
Common Challenges We Solve
- Poorly designed or underpowered trials
- Unclear dose selection or PK/PD strategy
- Delays in Phase I or II progression
- Regulatory concerns or feedback
- Lack of translational alignment
- Programs at risk of failure
Value to Clients
- Improve Probability of Success: Better trial and dosing design
- Accelerate Development: Reduced delays through planning
- Reduce Cost & Risk: Avoid failed trials
- Strengthen Regulatory Positioning: Meet global expectations
Who We Work With
- Biotech companies
- Pharmaceutical companies
- Venture capital and private equity firms
- Companies with complex therapeutic modalities
Why Our Approach Works
- Operator-Led Expertise
- Integrated Thinking
- Quantitative Focus
- Execution-Oriented
Bottom Line
We design and optimize clinical programs that improve decision-making, reduce risk,
and increase the likelihood of regulatory and commercial success.
Number of companies: 2
Number of contacts: 3
Back to Home
